FSTX News and Press, F-star Therapeutics Inc Com From 07/08/21

metamorworks/iStock via Getty Images F-star Therapeutics (FSTX) has added ~14.3% in the pre-market after announcing a licensing agreement with AstraZeneca (AZN) for next-generation Stimulator of Interferon Genes ((STING)) inhibitor compounds. Per the terms, Anglo-Swedish d...

metamorworks/iStock via Getty Images F-star Therapeutics (FSTX) has added ~14.3% in the pre-market after announcing a licensing agreement with AstraZeneca (AZN) for next-generation Stimulator of Interferon Genes ((STING)) inhibitor compounds. Per the terms, Anglo-Swedish d...

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”) , a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immu...

Two new sample breakout stocks for Week 25 with better than 10% short-term upside potential. This past week, the peak gains were in SOL +9.3% and INBX +7.3% with the Market and S&P 500 Momentum Gauges® turning the most negative since February. 2021 MDA minimal returns are...

Photo by goir/iStock via Getty Images Biogen’s Aducanumab pricing could reignite debate on drug price: Citi With a $56K/ year price tag for its newly-approved Alzheimer's disease treatment Aduhelm (aducanumab), Biogen (BIIB) has already generated criticism from lawmakers. The comp...

F-star Therapeutics, Inc. (FSTX) Q1 2021 Earnings Conference Call May 17, 2021 9:00 AM ET Company Participants Lindsey Trickett - Vice President of Investor Relations Eliot Forster - President and Chief Executive Officer Darlene Deptula-Hicks - Chief Financial Officer Conference Call Particip...

The following slide deck was published by F-star Therapeutics, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: F-star Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

F-star Therapeutics (FSTX): Q1 GAAP EPS of -$1.08 beats by $0.08.Revenue of $2.92M (+114.7% Y/Y) beats by $1.72M.Press Release For further details see: F-star Therapeutics EPS beats by $0.08, beats on revenue

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 17, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) , a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cance...

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today t...